PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions

American Journal of Roentgenology

Volumn 201, Issue 5, 2013, Pages

  Zhang, Tian ^a   Das, Shiva K ^b   Fels, Diane R ^c   Hansen, Katherine S ^d   Wong, Terence Z ^a   Dewhirst, Mark W ^b   Vlahovic, Gordana ^a  

^a DUKE UNIVERSITY HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Medpace ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hypoxia; Lung tumor; Perfusion; PET

Indexed keywords

COPPER 62; DIACETYL BIS (N 4 METHYLTHIOSEMICARBAZONE) CU 62; EPIDERMAL GROWTH FACTOR; FLUORODEOXYGLUCOSE; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 6; INTERLEUKIN 8; PYRUVALDEHYDE BIS (N 4 METHYLTHIOSEMICARBAZONE) CU 62; RADIOISOTOPE; UNCLASSIFIED DRUG; VASCULOTROPIN; COPPER (II) DIACETYL-DI(N(4)-METHYLTHIOSEMICARBAZONE); COPPER PYRUVALDEHYDE BIS(N(4)-METHYLTHIOSEMICARBAZONE) COMPLEX; CYTOKINE; FLUORODEOXYGLUCOSE F 18; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT; THIOSEMICARBAZONE DERIVATIVE; COPPER (II) DIACETYL DI(N(4) METHYLTHIOSEMICARBAZONE); COPPER PYRUVALDEHYDE BIS(N(4) METHYLTHIOSEMICARBAZONE) COMPLEX; DIAGNOSTIC AGENT;

AGED; BLOOD SAMPLING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOXIA; LANGERHANS CELL HISTIOCYTOSIS; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG GRANULOMA; LUNG LESION; LUNG NODULE; LUNG PERFUSION; MALE; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; RADIOISOTOPE DECAY; REVIEW; SARCOMATOID CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION; WEDGE RESECTION; ANOXIA; BLOOD; DIAGNOSTIC USE; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING; SURVIVAL RATE; ARTICLE; METHODOLOGY;

AGED; ANOXIA; CYTOKINES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SURVIVAL RATE; THIOSEMICARBAZONES;

EID: 84886458040     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.9698     Document Type: Review

References (23)

1. Howlader N, Noone AM, Krapcho M, et al.; National Cancer Institute. SEER cancer statistics review, 1975-2010. National Cancer Institute website. seer.cancer.gov/csr/1975-2010/. Accessed December 10, 2012
2. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer 2008; 8:967-975
3. Dewhirst MW. Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res 2009; 172:653-665
4. Moon EJ, Brizel DM, Chi JT, Dewhirst MW. The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid Redox Signal 2007; 9:1237-1294
5. Kim SJ, Rabbani ZN, Vollmer RT, et al. Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res 2004; 10:7925-7933
6. Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. Tumor uptake of copper-diacetylbis (N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 2001; 42:655-661
7. McCarthy DW, Bass LA, Cutler PD, et al. High purity production and potential applications of copper-60 and copper-61. Nucl Med Biol 1999; 26:351-358
8. 64Cu using a biomedical cyclotron. Nucl Med Biol 1997; 24:35-43
9. Green MA, Mathias CJ, Welch MJ, et al. Copper-62-labeled pyruvaldehyde bis(N4-methylthiosemicarbazonato) copper(II): synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion. J Nucl Med 1990; 31:1989-1996
10. Anderson CJ, Connett JM, Schwarz SW, et al. Copper-64-labeled antibodies for PET imaging. J Nucl Med 1992; 33:1685-1691
11. Xiao Z, Donnelly PS, Zimmermann M, Wedd AG. Transfer of copper between bis(thiosemicarbazone) ligands and intracellular copper-binding proteins: insights into mechanisms of copper uptake and hypoxia selectivity. Inorg Chem 2008; 47:4338-4347
12. 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med 2000; 14:323-328
13. 60Cu-labeled diacetylbis (N4-methylthiosemicarbazone). J Nucl Med 2008; 49:201-205
14. 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003; 30:844-850
15. 62Cu generator. AJR 2008; 190:427-432
16. Zhao B, Schwartz LH, Larson SM. Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers. J Nucl Med 2009; 50:239-249
17. 19F MRI to investigate tumor oxygenation. Magn Reson Med 2009; 62:357-364
18. Lee JW, Figeys D, Vasilescu J. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers. Adv Cancer Res 2007; 96:269-298
19. Goudar RK, Vlahovic G. Hypoxia, angiogenesis, and lung cancer. Curr Oncol Rep 2008; 10:277-282
20. Hiratsuka S, Maru Y, Okada A, et al. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 2001; 61:1207-1213
21. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006; 51:143-158
22. Allen TC. Pulmonary Langerhans cell histiocytosis and other pulmonary histiocytic diseases: a review. Arch Pathol Lab Med 2008; 132:1171-1181
23. Kim SJ, Rabbani ZN, Dewhirst MW, et al. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 2005; 49:325-335